Oruka Therapeutics ORKA General Counsel · filings 2024 to 2026 · sold $7.5M · $7.7M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 20, 2026 | Option or RSU exercised or converted | +9,000 | $7.80 | $70K | 38,995 direct | Filing · EDGAR |
| Oct 20, 2026 | Sale under a 10b5-1 plan | −400 | $74.90 | $30K | 38,595 direct | Filing · EDGAR |
| Oct 20, 2026 | Sale under a 10b5-1 plan | −500 | $76.12 | $38K | 38,095 direct | Filing · EDGAR |
| Oct 20, 2026 | Sale under a 10b5-1 plan | −1,000 | $77.21 | $77K | 37,095 direct | Filing · EDGAR |
| Oct 20, 2026 | Sale under a 10b5-1 plan | −4,100 | $78.79 | $323K | 32,995 direct | Filing · EDGAR |
| Oct 20, 2026 | Sale under a 10b5-1 plan | −3,000 | $79.49 | $238K | 29,995 direct | Filing · EDGAR |
| Oct 20, 2026 | Option or RSU exercised or converted Employee Warrant (right to buy) | −9,000 | 70,996 direct | Filing · EDGAR | ||
| Sep 21, 2026 | Option or RSU exercised or converted | +10,000 | $7.80 | $78K | 39,995 direct | Filing · EDGAR |
| Sep 21, 2026 | Sale under a 10b5-1 plan | −2,900 | $92.37 | $268K | 37,095 direct | Filing · EDGAR |
| Sep 21, 2026 | Sale under a 10b5-1 plan | −3,832 | $93.32 | $358K | 33,263 direct | Filing · EDGAR |
| Sep 21, 2026 | Sale under a 10b5-1 plan | −601 | $94.44 | $57K | 32,662 direct | Filing · EDGAR |
| Sep 21, 2026 | Sale under a 10b5-1 plan | −2,667 | $95.31 | $254K | 29,995 direct | Filing · EDGAR |
| Sep 21, 2026 | Option or RSU exercised or converted Employee Warrant (right to buy) | −10,000 | 79,996 direct | Filing · EDGAR | ||
| Sep 15, 2026 | Open-market or private sale | −1,039 | $95.71 | $99K | 29,995 direct | Filing · EDGAR |
| Aug 14, 2026 | Option or RSU exercised or converted | +10,000 | $7.80 | $78K | 41,034 direct | Filing · EDGAR |
| Aug 14, 2026 | Option or RSU exercised or converted | +42,000 | $12.50 | $525K | 83,034 direct | Filing · EDGAR |
| Aug 14, 2026 | Sale under a 10b5-1 plan | −3,630 | $106.05 | $385K | 79,404 direct | Filing · EDGAR |
| Aug 14, 2026 | Sale under a 10b5-1 plan | −10,434 | $107.14 | $1.1M | 68,970 direct | Filing · EDGAR |
| Aug 14, 2026 | Sale under a 10b5-1 plan | −14,696 | $107.97 | $1.6M | 54,274 direct | Filing · EDGAR |
| Aug 14, 2026 | Sale under a 10b5-1 plan | −10,200 | $109.11 | $1.1M | 44,074 direct | Filing · EDGAR |
| Aug 14, 2026 | Sale under a 10b5-1 plan | −9,193 | $110.00 | $1M | 34,881 direct | Filing · EDGAR |
| Aug 14, 2026 | Sale under a 10b5-1 plan | −3,847 | $111.14 | $428K | 31,034 direct | Filing · EDGAR |
| Aug 14, 2026 | Option or RSU exercised or converted Employee Warrant (right to buy) | −10,000 | 89,996 direct | Filing · EDGAR | ||
| Aug 14, 2026 | Option or RSU exercised or converted Employee Stock Option (right to buy) | −42,000 | 120,500 direct | Filing · EDGAR | ||
| Jun 15, 2026 | Open-market or private sale | −733 | $69.69 | $51K | 31,034 direct | Filing · EDGAR |
| Mar 16, 2026 | Open-market or private sale | −733 | $41.30 | $30K | 31,767 direct | Filing · EDGAR |
| Jan 23, 2026 | Grant or award from the company | +32,500 | 32,500 direct | Filing · EDGAR | ||
| Jan 23, 2026 | Grant or award from the company Employee Stock Option (right to buy) | +130,000 | 130,000 direct | Filing · EDGAR | ||
| Jan 22, 2025 | Grant or award from the company Employee Stock Option (right to buy) | +162,500 | 162,500 direct | Filing · EDGAR |
